Molecular Pharmaceutics

Carver Biosciences Announces Appointment of Three Members to its Scientific Advisory Board

Retrieved on: 
Tuesday, January 17, 2023
Biotechnology, Technology, Other Health, Health, General Health, Other Science, Research, Infectious Diseases, Nanotechnology, Genetics, Science, Infection, Severe acute respiratory syndrome coronavirus 2, Transdermal, UCPH Department of Biology, Editorial board, University of Washington Department of Bioengineering, Hepatitis B, NIH, United States Air Force Scientific Advisory Board, CRISPR, Associate, ERC, University, CRS, Internal medicine, Stanford University, Engineer, Degenerative disease, Chair, Pharmaceutics, RNA, Molecular Pharmaceutics, New York Genome Center, Scientist, Ludwig Maximilian University of Munich, Doctor of Philosophy, SNF, MIT, Nervous system, Physiology, BS, Y combinator, Computational linguistics, SAB, MS, PRDS, Drug resistance, JCR, Drug delivery, MIT Department of Brain and Cognitive Sciences, Cognitive science, Medical device, Pharmaceutical industry, Brain, Biology, Carver, List of life sciences, Neuroscience, New York University

Carver Biosciences, Inc., a biotech company focused on the development of CRISPR/Cas13 antivirals, today announced the formation of its Scientific Advisory Board (SAB).

Key Points: 
  • Carver Biosciences, Inc., a biotech company focused on the development of CRISPR/Cas13 antivirals, today announced the formation of its Scientific Advisory Board (SAB).
  • Cameron Myhrvold Ph.D., co-founder of Carver will serve as the chairman of the SAB.
  • Additional appointments include Uri Lopatin, M.D., Olivia Merkel, Ph.D., and Neville Sanjana, Ph.D.
    “I am thrilled to have Dr. Lopatin, Dr. Merkel and Dr. Sanjana join our advisory board,” said Dr. Walter Strapps, co-founder and CEO of Carver.
  • Dr. Sanjana holds a PhD in Brain and Cognitive Sciences from MIT, a BS in Symbolic Systems and a BA in English from Stanford University.

OliX Pharmaceuticals Publishes Preclinical Research Demonstrating OLX104C’s Potential as an Effective Treatment for Hair Loss

Retrieved on: 
Tuesday, November 22, 2022
Biotechnology, Health, Genetics, Pharmaceutical, Clinical Trials, University of Ulsan College of Medicine, Hair loss, KOSDAQ, Disorder, RNA interference, Therapy, University, Ulsan College, Asan Medical Center, AR, Treatment, Pharmaceutical industry, Molecular Pharmaceutics

OliX Pharmaceuticals, Inc. (KOSDAQ: 226950), a leading developer of RNAi therapeutics, today announced the publication of preclinical research on the androgenetic alopecia (hair loss) treatment program, OLX104C, in Molecular Pharmaceutics .

Key Points: 
  • OliX Pharmaceuticals, Inc. (KOSDAQ: 226950), a leading developer of RNAi therapeutics, today announced the publication of preclinical research on the androgenetic alopecia (hair loss) treatment program, OLX104C, in Molecular Pharmaceutics .
  • The Company is developing the treatment for androgenetic alopecia based on cell-penetrating asymmetric siRNA (cp-asiRNA) platform technology.
  • The research team demonstrated the efficacy of AR reduction, hair loss inhibition, and long duration of action in primary cultured human follicle dermal papilla cells (HFDPC) and rodent models of hair loss.
  • OliX Pharmaceuticals is a clinical-stage pharmaceutical company developing therapeutics against a variety of disorders by down-regulating the expression of disease-causing genes based on its own proprietary RNAi technology.